てんかん（癲癇）：世界医薬品市場予測及び市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 21
2.1 Catalyst 21
2.2 Upcoming Related Reports 22
3 Disease Overview 23
3.1 Classification of Seizures 25
3.2 Etiology and Pathophysiology 26
3.2.1 Etiology 26
3.2.2 Pathophysiology 29
3.2.3 Prognosis 34
3.2.4 Quality of Life 35
4 Epidemiology 36
4.1 Risk Factors and Comorbidities 36
4.1.1 Risk factors in newborns often include brain malformations and lack of oxygen 36
4.1.2 Genetic factors and head trauma are risk factors in adults and children 36
4.1.3 Common seizure triggers include lack of sleep, stress, and photosensitivity 37
4.1.4 Epilepsy comorbidities in adults and children include pain disorders 37
4.1.5 Anxiety and depression are major epilepsy comorbidities 37
4.1.6 Epilepsy with a known cause can be prevented by the avoidance of head injuries 38
4.2 Global Trends 38
4.2.1 United States 39
4.2.2 5EU Markets (France, Germany, Italy, Spain, and the UK) 40
4.2.3 Asia 41
4.3 Forecast Methodology 43
4.3.1 Sources Used 44
4.3.2 Forecast Assumptions and Methods 49
4.3.3 Sources Not Used 51
4.4 Epidemiologic Forecast 52
4.4.1 Total Active Prevalent Cases of Epilepsy 52
4.4.2 Total Lifetime Prevalent Cases of Epilepsy 54
4.4.3 Age-Specific Total Active Prevalent Cases of Epilepsy 56
4.4.4 Gender-Specific Total Active Prevalent Cases of Epilepsy 57
4.4.5 Seizure-Specific Total Active Prevalent Cases of Epilepsy 58
4.5 Discussion 59
4.5.1 Conclusion on Epidemiological Trends 59
4.5.2 Limitations of the Analysis 60
4.5.3 Strengths of the Analysis 60
5 Disease Management 61
5.1 Diagnosis 61
5.2 Treatment Guidelines 62
5.3 Clinical Practice 63
5.4 US 69
5.4.1 Diagnosis 69
5.4.2 Clinical Practice 71
5.5 UK 74
5.5.1 Diagnosis 74
5.5.2 Clinical Practice 75
5.6 France 76
5.6.1 Diagnosis 76
5.6.2 Clinical Practice 77
5.7 Germany 78
5.7.1 Diagnosis 78
5.7.2 Clinical Practice 79
5.8 Spain 81
5.8.1 Diagnosis 81
5.8.2 Clinical Practice 82
5.9 Italy 83
5.9.1 Diagnosis 83
5.9.2 Clinical Practice 84
5.10 Japan 85
5.10.1 Diagnosis 85
5.10.2 Clinical Practice 86
5.11 India 87
5.11.1 Diagnosis 87
5.11.2 Clinical Practice 87
5.12 China 89
5.12.1 Diagnosis 89
5.12.2 Clinical Practice 91
6 Competitive Assessment 93
6.1 Overview 93
6.2 Strategic Competitor Assessment 94
6.3 Product Profiles – Major Brands 97
6.3.1 Keppra (levetiracetam) 97
6.3.2 Lamictal (lamotrigine) 102
6.3.3 Lyrica (pregabalin) 107
6.3.4 Vimpat (lacosamide) 111
6.3.5 Zonegran (zonisamide) 115
6.3.6 Banzel/Inovelon (rufinamide) 120
6.3.7 Trobalt/Potiga (retigabine/ezogabine) 124
6.3.8 Zebinix (eslicarbazepine acetate) 127
6.3.9 Fycompa (perampanel) 131
6.3.10 Older-Generation AEDs 134
7 Opportunity and Unmet Need 136
7.1 Overview 136
7.2 Unmet Needs 137
7.2.1 Refractory Epilepsy 137
7.2.2 Safety/Side Effect Profiles 137
7.2.3 Curative/Disease-Modifying Agents 138
7.2.4 Predictive Tools and Need for More Directed Treatments 139
7.2.5 Improved Preclinical Models and Clinical Trial Paradigms 139
7.2.6 Treatment Gap 140
7.3 Unmet Needs Gap Analysis 141
7.4 Opportunities 142
7.4.1 Disease-Modifying Agents 142
7.4.2 Improved Preclinical Models and Clinical Trial Paradigms 142
7.4.3 Treatment Gap 142
8 Pipeline Assessment 143
8.1 Overview 143
8.2 Clinical Trial Mapping 143
8.2.1 Clinical Trials by Country 143
8.3 Clinical Trials by Phase and Trial Status 145
8.4 Strategic Pipeline Assessment 146
8.5 Pipeline by Phases of Development 147
8.5.1 Phase III Pipeline 147
8.5.2 Phase III Pipeline – Reformulations/New Delivery Systems 148
8.5.3 Phase IIb Pipeline 148
8.5.4 Phase II Pipeline 149
8.5.5 Phase I Pipeline 149
8.5.6 Preclinical Pipeline 150
8.5.7 Discovery Pipeline 151
8.6 Pipeline by Mechanism of Action 151
8.7 Promising Drugs in Clinical Development 153
8.7.1 Brivaracetam 154
8.7.2 Ganaxolone 157
8.7.3 VX-765 161
9 Current and Future Players 165
9.1 Overview 165
9.2 Trends in Corporate Strategy 168
9.3 Company Profiles 169
9.3.1 UCB 169
9.3.2 Eisai 171
9.3.3 Pfizer 172
9.3.4 GlaxoSmithKline 174
9.3.5 Novartis 175
9.3.6 Abbott 177
9.3.7 Dainippon Sumitomo Pharma 179
10 Market Outlook 181
10.1 Global Markets 181
10.1.1 Forecast 181
10.1.2 Drivers and Barriers – Global Issues 184
10.2 United States 186
10.2.1 Forecast 186
10.2.2 Key Events 189
10.2.3 Drivers and Barriers 189
10.3 France 191
10.3.1 Forecast 191
10.3.2 Key Events 194
10.3.3 Drivers and Barriers 194
10.4 Germany 195
10.4.1 Forecast 195
10.4.2 Key Events 199
10.4.3 Drivers and Barriers 199
10.5 Italy 201
10.5.1 Forecast 201
10.5.2 Key Events 204
10.5.3 Drivers and Barriers 204
10.6 Spain 206
10.6.1 Forecast 206
10.6.2 Key Events 209
10.6.3 Drivers and Barriers 209
10.7 United Kingdom 210
10.7.1 Forecast 210
10.7.2 Key Events 214
10.7.3 Drivers and Barriers 214
10.8 Japan 216
10.8.1 Forecast 216
10.8.2 Key Events 219
10.8.3 Drivers and Barriers 219
10.9 India 221
10.9.1 Forecast 221
10.9.2 Key Events 224
10.9.3 Drivers and Barriers 224
10.10 China 226
10.10.1 Forecast 226
10.10.2 Key Events 229
10.10.3 Drivers and Barriers 229
11 Appendix 231
11.1 Bibliography 231
11.2 Abbreviations 244
11.3 Methodology 247
11.4 Forecasting Methodology 247
11.4.1 Prevalent Epilepsy Patients 247
11.4.2 Percent Drug-Treated Patients 248
11.4.3 Drugs Included in Each Therapeutic Class Based on MOA 248
11.4.4 Launch Dates and Patent and Market Exclusivity Expiry Dates 249
11.4.5 General Pricing Assumptions 251
11.4.6 Individual Drug Assumptions 252
11.4.7 Generic Erosion 266
11.4.8 Pricing of Pipeline Agents 266
11.5 Physicians and Specialists Included in this Study 267
11.6 Primary Research – Prescriber Survey 268
11.7 About the Authors 269
11.7.1 Authors 269
11.7.2 Epidemiologist 270
11.7.3 Global Head of Healthcare 270
11.8 About GlobalData 271
11.9 Contact Us 271
11.10 Disclaimer 271